Cats Claim Record Share of Veterinary Visits as Feline Market Momentum Builds
The feline veterinary market is reaching an inflection point, according to newly released data from CATalyst Council showing cats now represent 23 percent of all clinical visits--the highest third-quarter proportion ever recorded. CATalyst Council Feline Veterinary Market Insights: Volume IV reveals that while overall companion-animal clinical visits have declined year over year since 2022, feline clinical visits continue their upward trajectory, extending a three-year pattern of growth that is reshaping the veterinary landscape.
Screening Cats for Osteoarthritis: How the Feline OA Checklist Can Transform Practice
Osteoarthritis (OA) in cats is common, underdiagnosed, and often overlooked until significant pain or mobility issues arise. A recent study published in the Journal of Feline Medicine and Surgery highlights a practical approach for identifying OA in feline patients using the Feline Osteoarthritis Checklist.
Cats Claim Record Share of Veterinary Visits as Feline Market Momentum Builds
The feline veterinary market is reaching an inflection point, according to newly released data from CATalyst Council showing cats now represent 23 percent of all clinical visits--the highest third-quarter proportion ever recorded. CATalyst Council Feline Veterinary Market Insights: Volume IV reveals that while overall companion-animal clinical visits have declined year over year since 2022, feline clinical visits continue their upward trajectory, extending a three-year pattern of growth that is reshaping the veterinary landscape.
Gallbladder Sludge in Cats: Much Ado About Nothing? New Study Challenges Common Assumptions
How many times have you been reviewing an abdominal ultrasound report on a vaguely sick cat and seen the phrase "gallbladder sludge noted"? If you're like most practitioners, that finding probably triggers a cascade of clinical decision-making: Is this cholangitis? Should I start antibiotics? Do I need to sample the bile? Is this why the cat isn't eating?
Veterinary cardiologist, Dr. Hayley McDonald Explains All about Felicyn CA-1
Felycin®-CA1 (sirolimus delayed-release tablets) is the first disease-modifying drug that can give hope to owners of cats with subclinical hypertrophic cardiomyopathy (HCM).Felycin®-CA1 is the first and only FDA conditionally approved once-weekly drug for the management of ventricular hypertrophy in cats with subclinical HCM.
Left Atrial Function as an Early Indicator of Thromboembolic Risk in Cats with HCM
Hypertrophic cardiomyopathy (HCM) remains the most common heart disease diagnosed in cats, and one of its most serious complications is the development of thromboembolism. Identifying early warning signs of clot formation is a critical step in improving outcomes for feline patients.